Anzeige
❌
Mehr »
Dienstag, 06.10.2026 - Börsentäglich über 12.000 News
US-Compliance: Kobalt-Ziele in zwei Ozeanen im Fokus
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
AP

WKN: A2QHK9 | ISIN: US82835W1080 | Ticker-Symbol:
NASDAQ
05.10.26 | 21:59
4,280 US-Dollar
0,00 % 0,000
1-Jahres-Chart
ARS PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
ARS PHARMACEUTICALS INC 5-Tage-Chart

Aktuelle News zur ARS PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
11.09.ARS Pharma auf der Cantor Global Healthcare: Strategiewechsel bei neffy soll Ärzte überzeugen4
22.08.ARS Pharma (SPRY) Cuts Spending As It Chases Neffy Market Share4
14.08.ARS Pharma targets cash flow breakeven by end of 2027 as it cuts cash-based SG&A and R&D to $100M-$110M in H2 20262
13.08.ARS Pharmaceuticals Reports Q2 2026 Results: Full Earnings Call Transcript3
ARS PHARMACEUTICALS Aktie jetzt für 0€ handeln
13.08.ARS Pharmaceuticals drops on abandoning DTC neffy marketing, Q2 EPS miss1
13.08.ARS Pharmaceuticals GAAP EPS of -$0.63 misses by $0.14, revenue of $33.7M beats by $2.38M2
13.08.ARS Pharmaceuticals, Inc. - 10-Q, Quarterly Report2
13.08.ARS Pharmaceuticals, Inc.: ARS Pharmaceuticals Outlines Strategic Priorities, including a Focused Commercial Strategy, and Reports Second Quarter 2026 Financial Results339$26.2 million in U.S. neffy® net product revenue in Q2 2026; total U.S. epinephrine market share for Type 1 allergies of 5% and 8% share within field-targeted accounts Commercial investment realigned...
► Artikel lesen
17.07.ARS Pharmaceuticals, Inc. - 8-K, Current Report2
15.07.ARS Pharmaceuticals (SPRY) Appoints Donn Casale As The New CEO3
09.07.Can ARS Pharma's New CEO Unlock Neffy's Potential?11
07.07.ARS Pharmaceuticals names Donn Casale as new CEO1
07.07.ARS Pharmaceuticals appoints new CEO1
07.07.ARS Pharmaceuticals, Inc. - 8-K, Current Report3
07.07.ARS Pharmaceuticals, Inc.: ARS Pharmaceuticals Announces CEO Succession386 Richard Lowenthal, Chief Executive Officer, Transitioning following More than a Decade of Leadership Since Co-Founding the Company Donn Casale, President, Appointed Chief Executive Officer and Director...
► Artikel lesen
25.06.ARS Pharmaceuticals, Inc. - 8-K, Current Report1
25.06.ARS Pharma Reaffirms 2027 Breakeven Goal Despite Missing July Neffy Coverage Wins1
25.06.Cantor Fitzgerald keeps Overweight on ARS Pharmaceuticals stock6
25.06.ARS Pharmaceuticals plunges 23% as neffy fails to secure insurance coverage5
25.06.ARS Pharmaceuticals (SPRY) Stock Sinks After-Hours After Commercial Update On Neffy Coverage19
1 2 3 Weiter >>
49 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1